Literature DB >> 34802545

Thrombotic manifestations of VEXAS syndrome.

Emma M Groarke1, Alina E Dulau-Florea2, Yogendra Kanthi3.   

Abstract

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently described autoinflammatory syndrome characterized by diffuse inflammatory manifestations, predisposition to hematological malignancy, and an association with a high rate of thrombosis. VEXAS is attributed to somatic mutations in the UBA1 gene in hematopoietic stem and progenitor cells with myeloid restriction in mature forms. The rate of thrombosis in VEXAS patients is approximately 40% in all reported cases to date. Venous thromboembolism predominates thrombotic events in VEXAS. These are classified as unprovoked in etiology, although systemic and vascular inflammation are implicated. Here, we review the clinical and laboratory characteristics in VEXAS that provide insight into the possible mechanisms leading to thrombosis. We present knowledge gaps in the mechanisms and management of VEXAS-associated thromboinflammation and propose areas for future investigation in the field. Published by Elsevier Inc.

Entities:  

Keywords:  Antiphospholipid syndrome; Autoimmune; Coagulation; Inflammation; Innate immune; Lupus anticoagulant; Monocyte; Myelodysplastic syndrome; Neutrophil; Thrombosis; Ubiquitin; VEXAS

Mesh:

Substances:

Year:  2021        PMID: 34802545     DOI: 10.1053/j.seminhematol.2021.10.006

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  2 in total

Review 1.  Update on VEXAS and role of allogeneic bone marrow transplant: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT.

Authors:  Carmelo Gurnari; Donal P McLornan
Journal:  Bone Marrow Transplant       Date:  2022-08-08       Impact factor: 5.174

Review 2.  Vasculitis associated with VEXAS syndrome: A literature review.

Authors:  Ryu Watanabe; Manami Kiji; Motomu Hashimoto
Journal:  Front Med (Lausanne)       Date:  2022-08-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.